(2022). Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database. Osteoporos Int. http://doi.org/10.1007/s00198-021-06262-1.
(2020). Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a bi-national cohort analysis. J Bone Miner Res. http://doi.org/10.1002/jbmr.4235.
(2020). Oral bisphosphonate use and all-cause mortality in patients with moderate-severe (grade 3B-5D) chronic kidney disease: a population-based cohort study. J Bone Miner Res. http://doi.org/10.1002/jbmr.3961.
(2021). One- and 2-year incidence of osteoporotic fracture: a multi-cohort observational study using routinely collected real-world data. Osteoporos Int. http://doi.org/10.1007/s00198-021-06077-0.
(2021). Predicting Imminent Fractures in Patients With a Recent Fracture or Starting Oral Bisphosphonate Therapy: Development and International Validation of Prognostic Models. J Bone Miner Res. http://doi.org/10.1002/jbmr.4414.
(2021). Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study. Health Technol Assess. http://doi.org/10.3310/hta25170.